Biomimetic Nanoparticle Development Service

Biomimetic Drug Delivery Systems (Biomimetic DDS)

Biomimetic drug delivery systems (Biomimetic DDS) leverage the synergy of nanoparticles and natural biomaterials to replicate intricate biological structures and processes. This innovative approach combines the versatility of nanoparticles with the safety and functionality of natural biomaterials. Creative Biolabs provides tailored biomimetic DDS solutions based on cell membranes, lipoproteins, exosomes, viruses, proteins, and peptides to meet your drug delivery needs.

Advantages of Biomimetic DDS

Biomimetic DDS derived from nature possesses complex functions that are difficult to achieve with purely artificial materials. Its multifaceted advantages can bring you unprecedented breakthroughs and possibilities in the field of drug delivery.

• Generating or achieving biological effects
  BBB permeability
• Maximum build-up at the target sites
• Excellent biocompatibility
• Protecting drugs from degradation
• Traditional routes of administration that are non-invasive
• Optimum utilization of existing drugs

We could Provide a Wide Selection of Biomimetic DDSs for You

We can provide you with customized biomimetic DDS to meet your research requirements for different functionalities (e.g., BBB-permeability, targeting, long circulation, low immunogenic) and drug properties (e.g., hydrophilic, hydrophobic, amphiphilic drugs, proteins, nucleic acids).

Classification	Description	Composition	Advantages	Applications	Figure
Cell membrane-based DDSs	Encapsulating nanoparticles within the cell membranes can generate biomimetic DDSs that mimic cellular membrane function. Cell membrane-based DDSs leverage the function of membrane proteins to actively traverse biological barriers, such as the blood-brain barrier (BBB), without relying on the effect of EPR, while avoiding undesired immune responses.	Erythrocyte; Leukocyte; Platelet; Stem cell; Cancer cells; Hybrid membrane.	It integrates the spatial stability of polysaccharides, immune activity of proteins, anchoring function of lipid bilayers, and drug-loading ability of nanoparticles into a single and unified platform.	Combining various cell membranes and nanoparticle cores.	Fig.1 Cell membrane-based DDSs.
Lipoprotein-based DDSs	Lipoprotein-based DDSs can evade the clearance of the mononuclear phagocyte system (MPS) and prolong circulation time by imitating the structure of lipoproteins. Lipoproteins can translocate across the cell membrane by being smaller than 30nm or by binding to surface receptors, which allows lipoprotein-based DDSs to traverse the BBB and achieve targeted effects.	Low-density lipoprotein; High-density lipoprotein.	Lipoproteins' small size allows them to overcome barriers and reach the target; Receptor-mediated transcellular effects; High BBB permeability; Evade the clearance of MPS; Carrying drugs with different physicochemical properties; Completely biodegradable.	Delivery of hydrophilic, hydrophobic, and amphiphilic drugs.	Fig.2 Lipoprotein-based DDSs.
Exosome-based DDSs	Extracellular vehicles (EVs) are membrane-containing vesicles released by cells. Exosomes are a subtype of EVs that originate from the inward budding of multivesicular bodies, whose size ranges from 30 to 150 nm.	Exosomes.	Highly biocompatible; Low-immunogenic; BBB-penetrating.	Delivery of small molecules and macromolecules, such as RNA and proteins.	Fig.3 Exosome-based DDSs.
Virus-based DDSs	Self-assembly or infusion can be used to encapsulate drugs in the virus-based DDS. We can manipulate capsid proteins by inserting, replacing, or disrupting sequences to provide you with a virus-based DDS that is controlled, targeted, and able to cross BBB.	Capsid protein.	Direct BBB crossing; Altered capsid protein for controlled targeting; Extends half-life.	Delivery of nucleic acids.	Fig.4 Virus-based DDSs.
Protein-based DDSs	Protein-based DDSs can penetrate BBB via transcytosis mediated by particular plasma membrane receptors. In addition, albumin and ferritin have innate targeting ability, which can be actively ingested by cells and provide essential nutrients. We can hydrophobically modify or cationize hydrophilic proteins to fulfill your demands for transporting hydrophobic medicines and nucleosides.	Albumin; Insulin; Insulin-like growth factor; Angiotensin II; Ferritin.	BBB permeability is mediated by specific plasma membrane receptors Innate active targeting ability.	Delivery of hydrophobic drugs and nucleic acids.	Fig.5 Protein-based DDSs.
Peptide-based DDSs	Peptide-based DDSs may increase BBB permeability by using receptor-mediated active targeting. These peptides function as ligands for endothelial cell receptors, bridging the gap between natural biomaterials and nanoparticles. We can provide non-cytotoxic and non-immunogenic biocompatible peptide-based DDSs for your systemic drug delivery needs.	Agiopep-2 peptide; ApoB peptide; ApoE peptide; RVG peptide; GSH peptide; TAT peptide.	Peptide modifications may improve the delivery of drug-loaded nanoparticles.	Systemic administration.	Fig.6 Peptide-based DDSs.

Why Choose Us?

Rapid, trustworthy, and cutting-edge technological infrastructure
Devise and implement smart, efficient solutions
Highly customized Biomimetic DDS
Highly collaborative and responsive customer service team
Competitive Pricing;
Strictest quality standards

Creative Biolabs has extensive experience in biomimetic DDS, and we can freely combine nanoparticles with the biomaterials you need. You will have access to a wide range of biomimetic nanoparticles with features such as targeting and controlled release if you choose us. Contact us and you will get the quickest and most effective solution.

For Research Use Only. Not For Clinical Use